Zealand Pharma Company Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.

It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.

The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism.

The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.

The company was incorporated in 1997 and is based in Søborg, Denmark.

Zealand Pharma A/S

Country	Denmark
Founded	1997
Industry	Biotechnology
Sector	Healthcare
Employees	253
CEO	Adam Steensberg

Contact Details

Address: Sydmarken 11 Søborg, 2860 Denmark
Phone	45 88 77 36 00
Website	zealandpharma.com

Stock Details

Ticker Symbol	ZEAL
Exchange	Nasdaq Copenhagen
Fiscal Year	January - December
Reporting Currency	DKK
ISIN Number	DK0060257814
SIC Code	2836

Key Executives

Name	Position
Adam Sinding Steensberg M.D.	President and Chief Executive Officer
Henriette Wennicke	Executive Vice President and Chief Financial Officer
Ivan Mourits Moller	Executive Vice President and Chief Operating Officer
Dr. David M. Kendall M.D.	Chief Medical Officer and Head of Research & Development
Mads Kronborg	Head of Investor Relations and Communication
Ravinder Singh Chahil	Executive Vice President and General Counsel
Christina Sonnenborg Bredal	Executive Vice President and Chief People Officer
Dr. Jens Damsgaard Mikkelsen M.D.	Head of Molecular Pharmacology
Dr. Danilo Verge	Head of Global Medical Affairs
Lykke Romer	Vice President and Head of Finance and Accounting